Comparison of the Effectiveness of Two Psycho-physical Interventions: Mindfulness Based Relapse Prevention (MBRP) and Unguided Meditative Relaxation in Patients With Alcohol Use Disorder

Sponsor
Centre Hospitalier Universitaire de Nīmes (Other)
Overall Status
Recruiting
CT.gov ID
NCT04598399
Collaborator
(none)
168
7
2
48.4
24
0.5

Study Details

Study Description

Brief Summary

Alcohol use disorder (AUD) is the second highest preventable cause of death in France. Only 3% of patients are prescribed approved drugs for reducing alcohol consumption or maintenance of abstinence. Increasing evidence supports the efficacy of psychotherapies such as cognitive and behavioral therapies (CBT) in AUD. However, some patients are resistant to CBT and the positive effects of CBT could wane over time, resulting in mid- and long-term relapses. Mindfulness practice is increasingly widespread in the United States and its efficacy in various fields appears very promising. The study investigators hypothesize that the Mindfulness Based Relapse Prevention (MBRP) program will be more efficient than a relaxation/meditation without guidance control program in AUD.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Mindfulness Based Relapse Prevention
  • Behavioral: Relaxation/ meditation
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
168 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Outcomes Assessor)
Masking Description:
In order to limit measurement and attrition biases, the patient will be kept unaware of the hypotheses concerning the details of the evaluated programs (MBRP or control) and the program expected to be superior
Primary Purpose:
Treatment
Official Title:
Comparison of the Effectiveness of Two Psycho-physical Interventions: Mindfulness Based Relapse Prevention (MBRP) and Unguided Meditative Relaxation in Patients With Alcohol Use Disorder
Actual Study Start Date :
Oct 20, 2021
Anticipated Primary Completion Date :
Apr 1, 2025
Anticipated Study Completion Date :
Nov 1, 2025

Arms and Interventions

Arm Intervention/Treatment
Experimental: MBRP program:

Behavioral: Mindfulness Based Relapse Prevention
7 x 60-120 minute sessions with different themes: Automatic pilot/triggers/relapse/high-risk situations/ mindfulness in daily life. There will be a welcoming time, with a focus on at-home practice and difficulties, a theoretical presentation of new concepts, practical meditation exercises and a debriefing.

Active Comparator: Standard care

Behavioral: Relaxation/ meditation
7 x 60-120 minute sessions each with a different sound from nature with unguided, closed relaxation group with a maximum of 12 participants

Outcome Measures

Primary Outcome Measures

  1. Reduction in number of heavy drinking days (HDD) over previous 4 weeks, between the last drinking period at inclusion and 6 months. [6 months]

    Alcohol Time Line Follow Back (TLFB) where a HDD = consummation of 4+ (for women) or 5+ (for men) drinks per day.

Secondary Outcome Measures

  1. Change in number of heavy drinking days (HDD) during the last 4 weeks, between the last drinking period at inclusion and 3 months between groups [3 months]

    Alcohol Time Line Follow Back (TLFB) where a HDD = consummation of 4+ (for women) or 5+ (for men) drinks per day.

  2. Change in number of heavy drinking days (HDD) during the last 4 weeks, between the last drinking period at inclusion and 12 months between groups [12 months]

    Alcohol Time Line Follow Back (TLFB) where a HDD = consummation of 4+ (for women) or 5+ (for men) drinks per day.

  3. Change in 4-week total alcohol consumption since baseline [3 months]

    number of drinks (1 glass = 1 unit according to grams alcohol)

  4. Change in 4-week total alcohol consumption since baseline [12 months]

    number of drinks (1 glass = 1 unit according to grams alcohol)

  5. Change in frequency of craving since baseline [3 months]

    version F of craving experience questionnaire (CEQ-F)

  6. Change in frequency of craving since baseline [6 months]

    version F of craving experience questionnaire (CEQ-F)

  7. Change in frequency of craving since baseline [12 months]

    version F of craving experience questionnaire (CEQ-F)

  8. Change in strength of craving since baseline [3 months]

    version S of craving experience questionnaire (CEQ-S)

  9. Change in strength of craving since baseline [6 months]

    version S of craving experience questionnaire (CEQ-S)

  10. Change in strength of craving since baseline [12 months]

    version S of craving experience questionnaire (CEQ-S)

  11. Anxiety at baseline [Baseline]

    Beck Anxiety Inventory depression (BAI): 21-item self-assessment scale assessing anxiety

  12. Change in anxiety since baseline [3 months]

    Beck Anxiety Inventory depression (BAI): 21-item self-assessment scale assessing anxiety

  13. Change in anxiety since baseline [6 months]

    Beck Anxiety Inventory depression (BAI): 21-item self-assessment scale assessing anxiety

  14. Change in anxiety since baseline [12 months]

    Beck Anxiety Inventory depression (BAI): 21-item self-assessment scale assessing anxiety

  15. Depression at baseline [Baseline]

    Beck Depression Inventory (BDI): 21 items assessing the presence and severity of depressive symptoms

  16. Change in depression since baseline [3 months]

    Beck Depression Inventory (BDI): 21 items assessing the presence and severity of depressive symptoms

  17. Change in depression since baseline [6 months]

    Beck Depression Inventory (BDI): 21 items assessing the presence and severity of depressive symptoms

  18. Change in depression since baseline [12 months]

    Beck Depression Inventory (BDI): 21 items assessing the presence and severity of depressive symptoms

  19. Change in quality of life since baseline [3 months]

    Alcohol Quality of Life Scale (AQoLS): 34-item patient-reported questionnaire

  20. Change in quality of life since baseline [6 months]

    Alcohol Quality of Life Scale (AQoLS): 34-item patient-reported questionnaire

  21. Change in quality of life since baseline [12 months]

    Alcohol Quality of Life Scale (AQoLS): 34-item patient-reported questionnaire

  22. Emotion regulation at baseline [Baseline]

    Emotion Regulation Questionnaire (ERQ): 10-item scale designed to assessing Cognitive Reappraisal and Expressive Suppression on a 7-point Likert-type scale ranging from 1 (strongly disagree) to 7 (strongly agree).

  23. Change in emotion regulation since baseline [3 months]

    Emotion Regulation Questionnaire (ERQ): 10-item scale designed to assessing Cognitive Reappraisal and Expressive Suppression on a 7-point Likert-type scale ranging from 1 (strongly disagree) to 7 (strongly agree).

  24. Change in emotion regulation since baseline [6 months]

    Emotion Regulation Questionnaire (ERQ): 10-item scale designed to assessing Cognitive Reappraisal and Expressive Suppression on a 7-point Likert-type scale ranging from 1 (strongly disagree) to 7 (strongly agree).

  25. Change in emotion regulation since baseline [12 months]

    Emotion Regulation Questionnaire (ERQ): 10-item scale designed to assessing Cognitive Reappraisal and Expressive Suppression on a 7-point Likert-type scale ranging from 1 (strongly disagree) to 7 (strongly agree).

  26. Difficulties regulating emotion at baseline [Baseline]

    Difficulties in Emotion Regulation scale (DERS -Impulse): items 3, 14, 19, 24R, 27, 32 from DERS

  27. Changes in difficulties regulating emotion since baseline [3 months]

    Difficulties in Emotion Regulation scale (DERS -Impulse): items 3, 14, 19, 24R, 27, 32 from DERS

  28. Changes in difficulties regulating emotion since baseline [6 months]

    Difficulties in Emotion Regulation scale (DERS -Impulse): items 3, 14, 19, 24R, 27, 32 from DERS

  29. Changes in difficulties regulating emotion since baseline [12 months]

    Difficulties in Emotion Regulation scale (DERS -Impulse): items 3, 14, 19, 24R, 27, 32 from DERS

  30. Changes in impulsivity since baseline [3 months]

    Impulsive behavior scale (UPPS-P): 20-item self-assessment scale

  31. Impulsivity at baseline [Baseline]

    Impulsive behavior scale (UPPS-P): 20-item self-assessment scale

  32. Changes in impulsivity since baseline [6 months]

    Impulsive behavior scale (UPPS-P): 20-item self-assessment scale

  33. Changes in impulsivity since baseline [12 months]

    Impulsive behavior scale (UPPS-P): 20-item self-assessment scale

  34. Changes in coping mechanism [3 months]

    brief COPE questionnaire: 14 scales including 2 items (28 items in total)

  35. Coping mechanism at baseline [Baseline]

    brief COPE questionnaire: 14 scales including 2 items (28 items in total)

  36. Changes in coping mechanism [6 months]

    brief COPE questionnaire: 14 scales including 2 items (28 items in total)

  37. Changes in coping mechanism [12 months]

    brief COPE questionnaire: 14 scales including 2 items (28 items in total)

  38. Cognitive impairment [Baseline]

    Montreal Cognitive Assessment (MoCA)

  39. Initial mindfulness [Baseline]

    Five Facets Mindfulness Questionnaire (FFMQ): 39-item self-assessment tool measuring 5 factors of mindfulness

  40. Number of meditation sessions per week over the last 4 weeks [Month 6]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Having a moderate to severe alcohol use disorder according to DSM 5 criteria.

  • The last drink must have been consumed at most in the last 30 days before the pre-inclusion visit. The patient must have had at least 1 HDD during the last drinking period

Exclusion Criteria:
  • Severe depression (Beck Depression Inventory> 30)

  • Schizophrenic disorder,

  • Current maniac or hypomaniac episode,

  • Patient with dementia or severe cognitive impairment that would prevent him/her from following the course of a session, as judged by the clinician.

  • Insufficient French understanding to complete the questionnaires

  • Pregnant or breastfeeding woman

  • Absence of social security regimen

  • Other mindfulness-based structured therapies

  • Refusal to sign the written consent. • The patient is under safeguard of justice or state guardianship

Contacts and Locations

Locations

Site City State Country Postal Code
1 Hôpital Corentin-Celton Issy-les-Moulineaux France
2 CHU de Nantes Nantes France
3 CHU de Nimes Nîmes France
4 Clinique Des Epinettes Paris France
5 Hopital Pitié-Salpétriere Paris France
6 Le CSAPA - Association Charonne Paris France
7 Hopital Paul Brousse Villejuif France

Sponsors and Collaborators

  • Centre Hospitalier Universitaire de Nīmes

Investigators

  • Principal Investigator: Amandine Luquiens, CHU Nimes

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Centre Hospitalier Universitaire de Nīmes
ClinicalTrials.gov Identifier:
NCT04598399
Other Study ID Numbers:
  • PHRCN/2018/AL-01
First Posted:
Oct 22, 2020
Last Update Posted:
Jul 21, 2022
Last Verified:
Jul 1, 2022
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 21, 2022